Travere Therapeutics (TVTX) Total Liabilities (2011 - 2026)

Travere Therapeutics has reported Total Liabilities for 16 years, with the latest figure at $456.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 11.53% year-over-year to $456.5 million; the trailing twelve-month figure through Mar 2026 stood at $456.5 million (down 11.53% YoY), and the FY2025 full-year result was $490.4 million, down 8.35% from the prior year.
• Total Liabilities for Q1 2026 stood at $456.5 million, down from $490.4 million in the prior quarter.
• The five-year high for Total Liabilities was $629.7 million in Q4 2022, with the low at $456.5 million in Q1 2026.
• Historically, Total Liabilities has averaged $560.3 million across 5 years, with a median of $553.1 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 54.54% — and 2024, when it fell 13.54%.
• Travere Therapeutics' Total Liabilities stood at $629.7 million in 2022, then decreased by 6.61% to $588.1 million in 2023, then dropped by 9.02% to $535.0 million in 2024, then decreased by 8.35% to $490.4 million in 2025, then retreated by 6.91% to $456.5 million in 2026.
• The last three Total Liabilities figures came in at $456.5 million (Q1 2026), $490.4 million (Q4 2025), and $465.0 million (Q3 2025), per Business Quant data.